ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Regulation FD Disclosure

Item 7.01.Regulation FD Disclosure.

On May 16, 2017, Ultragenyx Pharmaceutical Inc. posted an updated
Corporate Presentation to its website at www.ultragenyx.com in
the Events Presentations subsection of the Investors tab.

The information set forth under Item 7.01 and in the Corporate
Presentation shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
reference in any such filing.

About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Recent Trading Information

ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) closed its last trading session up +0.91 at 58.86 with 203,925 shares trading hands.